CEO Alexandra MacLean was paid $840,100 in fiscal year 2024, ↓ down 30.8% from fiscal year 2023 (SEC filing 0001437749-25-037023 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$840,100 ↓ Alexandra MacLean total, FY2024 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | 98.67% Say-on-pay support, latest vote |
ATXI's next annual pay disclosure, estimated December 5, 2026.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Alexandra MacLean | $420,000 | $0 | $406,300 | $0 | $0 | $0 | $13,800 | $840,100 |
| Chief Executive Officer | ||||||||
| David Jin | 0 | 0 | 155,350 | 0 | 0 | 0 | 0 | 155,350 |
| Interim Chief Financial Officer and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Alexandra MacLean | $840,100 | $1,213,200 | — | ↓ −373,100 |
| David Jin | 155,350 | 260,000 | — | ↓ −104,650 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Avenue Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ATXI reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses ATXI in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ATXI in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Alexandra MacLean | RSU | 85,000 | — | $170,000 |
| David Jin | RSU | 32,500 | — | 65,000 |
| Alexandra MacLean | Option | 5,332 | 85.5 | — |
| David Jin | Option | 1,667 | 85.5 | — |
The Company's compensation program is designed to attract, retain, and motivate highly qualified executives by providing competitive base salaries and discretionary annual bonuses based on corporate factors and individual performance, alongside long-term equity awards to align executive interests with stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2023 | 2023-06-22 | 9,541,965 | 128,472 | 32,597 | 98.67% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2023 | 2023-06-22 | 98.67%a |
a. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jay Kranzler, M.D., PhDIndependent · Board Chair | $60,000 | — | $64,530 | — | $50,000 | $174,530 |
| Neil HerskowitzIndependent · Audit (Chair) | 60,000 | — | 64,530 | — | 0 | 124,530 |
| Curtis OltmansIndependent · Audit · Compensation (Chair) | 50,000 | — | 64,530 | — | 0 | 114,530 |
| Faith CharlesIndependent · Audit | 50,000 | — | 64,530 | — | 0 | 114,530 |
| Lindsay A. Rosenwald, M.DNot independent | 0 | — | 64,530 | — | 0 | 64,530 |
| Alexandra MacLean, M.DEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $30,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $220,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $50,000 |
| Total cost of the board | $270,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Avenue Therapeutics | 2024 | Alexandra MacLean | $420,000 | $406,300 | $0 | $0 | $840,100 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Alexandra MacLean | DEF 14A | 2025-12-05 | 0001437749-25-037023 | Section “Summary Compensation Table”. As printed: 840,100. Filing ↗machine: r2 · c28 · span 237985–237992 |
| 2 | Section 01, David Jin | DEF 14A | 2025-12-05 | 0001437749-25-037023 | Section “Summary Compensation Table”. As printed: 155,350. Filing ↗machine: r4 · c28 · span 244414–244421 |
| 3 | Section 08, Jay Kranzler, M.D., PhD | DEF 14A | 2025-12-05 | 0001437749-25-037023 | Section “Director Compensation”. As printed: 174,530. Filing ↗machine: span 291857–291864 |
| 4 | Section 08, Neil Herskowitz | DEF 14A | 2025-12-05 | 0001437749-25-037023 | Section “Director Compensation”. As printed: 124,530. Filing ↗machine: span 295951–295958 |
| 5 | Section 08, Curtis Oltmans | DEF 14A | 2025-12-05 | 0001437749-25-037023 | Section “Director Compensation”. As printed: 114,530. Filing ↗machine: span 297998–298005 |
| 6 | Section 08, Faith Charles | DEF 14A | 2025-12-05 | 0001437749-25-037023 | Section “Director Compensation”. As printed: 114,530. Filing ↗machine: span 293903–293910 |
| 7 | Section 08, Lindsay A. Rosenwald, M.D | DEF 14A | 2025-12-05 | 0001437749-25-037023 | Section “Director Compensation”. As printed: 64,530. Filing ↗machine: span 289157–289163 |
| 8 | Section 08, Alexandra MacLean, M.D | DEF 14A | 2025-12-05 | 0001437749-25-037023 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 9 | Section 06, 2023 vote | Form 8-K | 2023-06-26 | 0001104659-23-074745 | Item 5.07 · say-on-pay result. As reported: 98.67% (votes for as printed: 9,541,965). Filing ↗ |
| 10 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 11 | Section 09b board cost (computed) | Computed | — | — | Cash 220,000 + equity 0 + all other 50,000 = 270,000, summed across the director compensation table rows.machine: formula: Σ = 270,000 |
| 12 | Avenue Therapeutics (subject), Section 10b CEO total | DEF 14A | 2025-12-05 | 0001437749-25-037023 | CEO total compensation as printed in Avenue Therapeutics's own proxy. As printed: 840,100. Filing ↗machine: r2 · c28 · span 237985–237992 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat